Skip to content
Hester Biosciences logo

Hester Biosciences

HESTERBIO NSE
₹2,243.70 90.80 (4.22%)
Market Cap
₹1,909 Cr
P/E
14.02

Hester Biosciences (HESTERBIO) share price was ₹2,243.70 at the 28 Oct 2026 close; market capitalisation ₹1,909 Cr; P/E (TTM) 14.02; sector Healthcare. The share price rose 38.4% over the year to 28 Oct 2026 (adjusted for splits and bonuses). In the Jun 2026 quarter, revenue fell 8.2% year on year to ₹77.2 Cr and net profit was ₹97 Cr, against ₹17 Cr a year earlier (compared with Jun 2025). Promoters held 44.28% of Hester Biosciences in Sep 2026, down 9.45 percentage points from Jun 2026. Its Tapetide Score is 55/100 (Good) as of 28 Oct 2026.

Close 28 Oct 2026 ₹2,243.70 +622.20 +38.37% 1Y

Key Fundamentals

MicrocapPharmaceuticals & BiotechnologyHealthcare
Market Cap
₹1,909 Cr
P/E (TTM)
14.02
EBITDA
₹96.30 Cr
Return on Equity
15.63%
Debt to Equity
0.54
Book Value
₹423.46
EPS (TTM)
₹160.08
52W High
₹2,683.60
52W Low
₹1,239.30

Price-based figures as of 28 Oct 2026, 15:31 IST · EPS basis: Consolidated · TTM

Peer Comparison

Healthcare › Pharmaceuticals

Sun Pharma
₹1,757.5034.864,21,683 Cr5.050.91%13.79%17.94%61,848 Cr12,117 Cr
Divis Laboratories
₹9,558.5086.752,53,748 Cr15.140.32%15.32%18.96%11,682 Cr2,925 Cr
Torrent Pharmaceuticals
₹4,557.0071.541,73,334 Cr9.430.82%12.16%9.06%17,058 Cr2,156 Cr
Laurus Labs
₹2,181.90107.801,17,891 Cr22.240.09%16.38%19.67%7,323 Cr1,090 Cr
Zydus Life Science
₹1,175.5026.161,17,257 Cr4.330.09%16.99%19.24%28,515 Cr4,593 Cr
Dr Reddys Laboratories
₹1,335.4034.591,11,463 Cr2.870.61%10.87%13.94%34,247 Cr3,184 Cr
Cipla
₹1,365.6032.721,10,321 Cr3.120.96%11.21%14.88%28,589 Cr3,356 Cr
Hester Biosciences (this company)
₹2,243.7014.021,909 Cr5.300.51%15.63%16.51%431 Cr137 Cr
Median 8 companies₹1,969.7034.731,17,574 Cr5.180.56%14.56%17.23%22,787 Cr3,055 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the live price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100. How it works →

As of 2026-10-28
v2.0.0
55 Good
Overall score
Data confidence 100/100

Category scores

Quality Good 62
Returns, margins, earnings quality 22%
Valuation Strong 76
Cheap vs sector & own history 24%
Growth Poor 19
Sales & profit trajectory 9%
Financial Health Average 46
Solvency, leverage, coverage 9%
Momentum Good 66
Trend strength, vol-adjusted 12%
Ownership Weak 38
FII/DII/promoter flows 24%

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

2
  • Company has been maintaining a healthy dividend payout of 21.8%
  • Company's working capital requirements have reduced from 80.2 days to 54.4 days

Weaknesses

5
  • Stock is trading at 4.89 times its book value
  • The company has delivered a poor sales growth of 9.19% over past five years.
  • Company has a low return on equity of 10.8% over last 3 years.
  • Company might be capitalizing the interest cost
  • Earnings include an other income of Rs.105 Cr.

Technical Indicators

Oscillators

BearishNeutralBullish

Bullish

Bearish
1
Neutral
6
Bullish
2

Overall

BearishNeutralBullish

Bullish

Bearish
2
Neutral
6
Bullish
11

Moving Averages

BearishNeutralBullish

Bullish

Bearish
1
Neutral
0
Bullish
9

Growth Rate

Revenue Growth
8.67% higher than 3Y

change over 1 year

Net Income Growth
99.65% higher than 3Y

change over 1 year

Cash Flow Change
-0.57%

change over 1 year

EBITDA Margin Change
36.45%

change over 1 year Operating margin 29% · Jun 2026

Quarterly Results

Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
88
70
67
79
82
84
63
82
84
71
77
100
77
Expenses
73
57
57
63
65
65
58
63
61
59
60
66
54
Operating Profit
14
13
10
16
18
19
5
19
23
12
18
34
23
OPM %
16%
19%
15%
20%
21%
23%
8%
23%
27%
17%
23%
34%
29%
Other Income
3
6
2
5
2
3
9
-6
3
12
2
2
89
Interest
3
8
2
7
5
6
-4
6
2
2
2
5
3
Depreciation
5
4
4
4
4
4
4
4
4
4
4
6
7
PBT
9
7
6
10
11
12
13
4
20
17
14
25
102
Tax %
25%
40%
37%
35%
29%
29%
15%
59%
14%
16%
31%
34%
5%
Net Profit
7
4
4
6
7
8
11
2
17
14
9
17
97
EPS (₹)
6.9
4.81
4.68
5.82
7.45
9.64
13.71
1.52
19.33
16.99
10.31
18.78
114
Figures in ₹ Crores

Profit & Loss

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
90
101
123
136
178
183
214
235
266
305
311
333
326
Expenses
64
67
82
89
110
128
146
175
215
251
250
246
239
Operating Profit
25
34
41
47
68
55
69
60
51
54
62
87
87
OPM %
28%
34%
33%
35%
38%
30%
32%
26%
19%
18%
20%
26%
27%
Other Income
3
1
0
3
7
6
1
14
20
15
8
19
105
Interest
5
4
4
4
7
7
7
4
9
20
13
11
12
Depreciation
6
6
7
10
12
13
13
17
21
17
17
19
22
PBT
18
25
31
36
57
41
50
54
40
32
40
76
157
Tax %
26%
23%
26%
36%
28%
25%
31%
26%
30%
34%
27%
24%
—
Net Profit
13
19
23
23
41
31
35
39
28
21
29
57
137
EPS (₹)
15.99
22.57
27.68
30.12
48.87
34.29
40.47
46.22
31.3
22.21
32.31
65.41
160
Div. Payout %
19%
18%
19%
33%
23%
19%
25%
22%
26%
27%
22%
17%
—
Figures in ₹ Crores

Balance Sheet

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
9
9
9
9
9
9
9
9
9
9
9
9
Reserves
76
93
113
132
169
193
220
251
271
283
306
352
Borrowings
55
59
66
69
90
121
105
228
274
244
213
195
Other Liabilities
20
25
25
35
32
65
78
74
116
126
126
123
Total Liabilities
160
186
213
244
299
387
411
562
670
662
653
678
Fixed Assets
60
65
102
110
145
143
133
237
259
240
233
411
CWIP
33
36
21
32
7
74
109
82
149
171
183
9
Investments
0
0
0
0
0
0
0
21
25
30
34
43
Other Assets
68
85
89
102
148
170
169
222
237
221
203
215
Total Assets
160
186
213
244
299
387
411
562
670
662
653
678
Figures in ₹ Crores

Cash Flow

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
20
19
35
38
47
37
58
9
24
48
65
64
Investing
-21
-13
-30
-26
-21
-73
-42
-117
-77
-22
-20
-18
Financing
7
-7
2
-11
3
19
-18
112
42
-26
-52
-49
Net Cash Flow
5
-1
6
1
28
-17
-2
3
-12
0
-7
-3
Free Cash Flow
1
5
5
15
24
-36
17
-87
-54
24
44
47
CFO/OP
100
74
102
100
92
86
105
43
63
112
123
90
Figures in ₹ Crores

Ratios

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
72
95
79
87
67
116
84
86
109
94
86
105
Inventory Days
431
627
376
505
540
834
452
424
399
288
291
323
Days Payable
68
109
84
100
93
261
204
101
141
98
122
110
Cash Conversion Cycle
434
614
371
491
514
690
332
409
367
284
255
318
Working Capital Days
76
112
90
82
106
104
134
113
88
112
74
54
ROCE %
15%
19%
19%
20%
26%
16%
18%
14%
9%
9%
10%
15%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Hester Biosciences insights

72 extracted metrics + investor summaries across FY11–FY27.

Shareholding Pattern

DIIs0.08%Promot.44.28%FIIs0.31%Others22.63%Public32.70%As ofSep 2026

Documents

Frequently Asked Questions about Hester Biosciences

What does Hester Biosciences Ltd do?
Incorporated in 1987, Hester Biosciences Ltd is one of India’s leading animal healthcare companies and a major manufacturer of poultry and animal vaccines, including a leading position in PPR and Goat Pox vaccines.[1]
Where is Hester Biosciences Ltd (HESTERBIO) listed?
Hester Biosciences Ltd trades as HESTERBIO on the NSE and under code 524669 on the BSE.
Which sector does Hester Biosciences Ltd belong to?
Hester Biosciences Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Hester Biosciences Ltd?
Hester Biosciences Ltd has a market capitalisation of ₹1,909 Cr as of 28 Oct 2026, which places it in the Small Cap band.
What is the PE ratio of Hester Biosciences Ltd?
Hester Biosciences Ltd trades at a PE ratio of 14.02 as of 28 Oct 2026, on earnings per share of ₹160.08, against a book value of ₹423.46 per share.
What is the 52-week high and low of Hester Biosciences Ltd?
Over the last 52 weeks Hester Biosciences Ltd has traded between ₹1,239.3 and ₹2,683.6 as of 28 Oct 2026.
Does Hester Biosciences Ltd pay dividends?
Hester Biosciences Ltd has a dividend yield of 0.51%.
What is the Return on Equity (ROE) of Hester Biosciences Ltd?
Hester Biosciences Ltd reported a return on equity of 15.63%. Its debt-to-equity ratio is 0.54.

Company Information

Incorporated in 1987, Hester Biosciences Ltd is one of India’s leading animal healthcare companies and a major manufacturer of poultry and animal vaccines, including a leading position in PPR and Goat Pox vaccines.[1]

Website hester.in
CEO Mr. Rajiv Dinesh Gandhi B.Com
Employees 562
Listed 2015-03-13
Face Value ₹ 10
Shares Outstanding 85,06,865

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/HESTERBIO.md for Hester Biosciences Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month